BACKGROUND: The collateral circulation is important in maintenance of blood supply to the ischemic kidney distal to renal artery stenosis (RAS). Obesity metabolic syndrome (MetS) preserves renal blood flow (RBF) in the stenotic kidney, but whether this is related to an increase of collateral vessel growth is unknown. We hypothesized that MetS increased collateral circulation around the renal artery. METHODS: Twenty-one domestic pigs were randomly divided into unilateral RAS fed an atherogenic (high-fat/high-fructose, MetS-RAS) or standard diet, or controls (n = 7 each). RBF, glomerular filtration rate (GFR), and the peristenotic collateral circulation were assessed after 10 weeks using multidetector computed tomography (CT) and the intrarenal microcirculation by micro-CT. Vascular endothelial growth factor (VEGF) expression was studied in the renal artery wall, kidney, and perirenal fat. Renal fibrosis and stiffness were examined by trichrome and magnetic resonance elastography. RESULTS: Compared with controls, RBF and GFR were decreased in RAS, but not in MetS-RAS. MetS-RAS formed peristenotic collaterals to the same extent as RAS pigs but induced greater intrarenal microvascular loss, fibrosis, stiffness, and inflammation. MetS-RAS also attenuated VEGF expression in the renal tissue compared with RAS, despite increased expression in the perirenal fat. CONCLUSIONS: MetS does not interfere with collateral vessel formation in the stenotic kidney, possibly because decreased renal arterial VEGF expression offsets its upregulation in perirenal fat, arguing against a major contribution of the collateral circulation to preserve renal function in MetS-RAS. Furthermore, preserved renal function does not protect the poststenotic kidney from parenchymal injury.
BACKGROUND: The collateral circulation is important in maintenance of blood supply to the ischemic kidney distal to renal artery stenosis (RAS). Obesity metabolic syndrome (MetS) preserves renal blood flow (RBF) in the stenotic kidney, but whether this is related to an increase of collateral vessel growth is unknown. We hypothesized that MetS increased collateral circulation around the renal artery. METHODS: Twenty-one domestic pigs were randomly divided into unilateral RAS fed an atherogenic (high-fat/high-fructose, MetS-RAS) or standard diet, or controls (n = 7 each). RBF, glomerular filtration rate (GFR), and the peristenotic collateral circulation were assessed after 10 weeks using multidetector computed tomography (CT) and the intrarenal microcirculation by micro-CT. Vascular endothelial growth factor (VEGF) expression was studied in the renal artery wall, kidney, and perirenal fat. Renal fibrosis and stiffness were examined by trichrome and magnetic resonance elastography. RESULTS: Compared with controls, RBF and GFR were decreased in RAS, but not in MetS-RAS. MetS-RAS formed peristenotic collaterals to the same extent as RAS pigs but induced greater intrarenal microvascular loss, fibrosis, stiffness, and inflammation. MetS-RAS also attenuated VEGF expression in the renal tissue compared with RAS, despite increased expression in the perirenal fat. CONCLUSIONS: MetS does not interfere with collateral vessel formation in the stenotic kidney, possibly because decreased renal arterialVEGF expression offsets its upregulation in perirenal fat, arguing against a major contribution of the collateral circulation to preserve renal function in MetS-RAS. Furthermore, preserved renal function does not protect the poststenotic kidney from parenchymal injury.
Authors: Alexis Cutchins; Daniel B Harmon; Jennifer L Kirby; Amanda C Doran; Stephanie N Oldham; Marcus Skaflen; Alexander L Klibanov; Nahum Meller; Susanna R Keller; James Garmey; Coleen A McNamara Journal: Arterioscler Thromb Vasc Biol Date: 2011-11-10 Impact factor: 8.311
Authors: Xin Zhang; Zi-Lun Li; John R Woollard; Alfonso Eirin; Behzad Ebrahimi; John A Crane; Xiang-Yang Zhu; Aditya S Pawar; James D Krier; Kyra L Jordan; Hui Tang; Stephen C Textor; Amir Lerman; Lilach O Lerman Journal: Am J Physiol Renal Physiol Date: 2013-05-08
Authors: Zi-Lun Li; John R Woollard; Behzad Ebrahimi; John A Crane; Kyra L Jordan; Amir Lerman; Shen-Ming Wang; Lilach O Lerman Journal: Arterioscler Thromb Vasc Biol Date: 2012-03-01 Impact factor: 8.311
Authors: Alfonso Eirin; Xiang-Yang Zhu; Amrutesh S Puranik; Hui Tang; Kelly A McGurren; Andre J van Wijnen; Amir Lerman; Lilach O Lerman Journal: Kidney Int Date: 2017-02-24 Impact factor: 10.612
Authors: James D Krier; John A Crane; Alfonso Eirin; Xiang-Yang Zhu; Amir Lerman; Lilach O Lerman Journal: Am J Hypertens Date: 2012-12-13 Impact factor: 2.689
Authors: Xiang-Yang Zhu; Alejandro R Chade; Martin Rodriguez-Porcel; Michael D Bentley; Erik L Ritman; Amir Lerman; Lilach O Lerman Journal: Arterioscler Thromb Vasc Biol Date: 2004-08-12 Impact factor: 8.311
Authors: Xin Zhang; Alfonso Eirin; Zi-Lun Li; John A Crane; James D Krier; Behzad Ebrahimi; Aditya S Pawar; Xiang-Yang Zhu; Hui Tang; Kyra L Jordan; Amir Lerman; Stephen C Textor; Lilach O Lerman Journal: Kidney Int Date: 2013-04-24 Impact factor: 10.612
Authors: Mohsen Afarideh; Xin Zhang; Christopher M Ferguson; James F Glockner; Amir Lerman; Stephen C Textor; Lilach O Lerman Journal: Hypertension Date: 2020-06-08 Impact factor: 10.190
Authors: Xiao-Jun Chen; Xin Zhang; Kai Jiang; James D Krier; Xiangyang Zhu; Amir Lerman; Lilach O Lerman Journal: J Hypertens Date: 2019-10 Impact factor: 4.844
Authors: Yu Zhao; Xiangyang Zhu; Lei Zhang; Christopher M Ferguson; Turun Song; Kai Jiang; Sabena M Conley; James D Krier; Hui Tang; Ishran Saadiq; Kyra L Jordan; Amir Lerman; Lilach O Lerman Journal: Stem Cells Dev Date: 2020-08-03 Impact factor: 3.272